Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Receivables: 2021-2025

Historic Receivables for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $343,469.

  • InMed Pharmaceuticals' Receivables rose 20.64% to $343,469 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 18.13%. This contributed to the annual value of $465,104 for FY2025, which is 31.82% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Receivables stood at $343,469, which was down 26.15% from $465,104 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Receivables peaked at $465,104 during Q2 2025, and registered a low of $14,842 during Q3 2021.
  • For the 3-year period, InMed Pharmaceuticals' Receivables averaged around $278,178, with its median value being $284,695 (2024).
  • Per our database at Business Quant, InMed Pharmaceuticals' Receivables surged by 993.35% in 2023 and then declined by 29.58% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Receivables (Quarterly) stood at $50,304 in 2021, then skyrocketed by 62.31% to $81,647 in 2022, then spiked by 356.69% to $372,870 in 2023, then declined by 29.58% to $262,569 in 2024, then climbed by 20.64% to $343,469 in 2025.
  • Its Receivables was $343,469 in Q3 2025, compared to $465,104 in Q2 2025 and $367,813 in Q1 2025.